TY - JOUR
T1 - Intermittent Hypoxic Preconditioning
T2 - A Potential New Powerful Strategy for COVID-19 Rehabilitation
AU - Cai, Ming
AU - Chen, Xuan
AU - Shan, Jieling
AU - Yang, Ruoyu
AU - Guo, Qi
AU - Bi, Xia
AU - Xu, Ping
AU - Shi, Xiangrong
AU - Chu, Lixi
AU - Wang, Liyan
N1 - Funding Information:
This work was sponsored by Scientific Research Foundation of SUMHS (SSF-21-03-008) and the grant of the funding of Youth Fund Project of Research Planning Foundation on Humanities and Social Sciences of the Ministry of Education (20YJCZH001).
Publisher Copyright:
© Copyright © 2021 Cai, Chen, Shan, Yang, Guo, Bi, Xu, Shi, Chu and Wang.
PY - 2021/4/30
Y1 - 2021/4/30
N2 - COVID-19 is a highly infectious respiratory virus, which can proliferate by invading the ACE2 receptor of host cells. Clinical studies have found that the virus can cause dyspnea, pneumonia and other cardiopulmonary system damage. In severe cases, it can lead to respiratory failure and even death. Although there are currently no effective drugs or vaccines for the prevention and treatment of COVID-19, the patient’s prognosis recovery can be effectively improved by ameliorating the dysfunction of the respiratory system, cardiovascular systems, and immune function. Intermittent hypoxic preconditioning (IHP) as a new non-drug treatment has been applied in the clinical and rehabilitative practice for treating chronic obstructive pulmonary disease (COPD), diabetes, coronary heart disease, heart failure, hypertension, and other diseases. Many clinical studies have confirmed that IHP can improve the cardiopulmonary function of patients and increase the cardiorespiratory fitness and the tolerance of tissues and organs to ischemia. This article introduces the physiological and biochemical functions of IHP and proposes the potential application plan of IHP for the rehabilitation of patients with COVID-19, so as to provide a better prognosis for patients and speed up the recovery of the disease. The aim of this narrative review is to propose possible causes and pathophysiology of COVID-19 based on the mechanisms of the oxidative stress, inflammation, and immune response, and to provide a new, safe and efficacious strategy for the better rehabilitation from COVID-19.
AB - COVID-19 is a highly infectious respiratory virus, which can proliferate by invading the ACE2 receptor of host cells. Clinical studies have found that the virus can cause dyspnea, pneumonia and other cardiopulmonary system damage. In severe cases, it can lead to respiratory failure and even death. Although there are currently no effective drugs or vaccines for the prevention and treatment of COVID-19, the patient’s prognosis recovery can be effectively improved by ameliorating the dysfunction of the respiratory system, cardiovascular systems, and immune function. Intermittent hypoxic preconditioning (IHP) as a new non-drug treatment has been applied in the clinical and rehabilitative practice for treating chronic obstructive pulmonary disease (COPD), diabetes, coronary heart disease, heart failure, hypertension, and other diseases. Many clinical studies have confirmed that IHP can improve the cardiopulmonary function of patients and increase the cardiorespiratory fitness and the tolerance of tissues and organs to ischemia. This article introduces the physiological and biochemical functions of IHP and proposes the potential application plan of IHP for the rehabilitation of patients with COVID-19, so as to provide a better prognosis for patients and speed up the recovery of the disease. The aim of this narrative review is to propose possible causes and pathophysiology of COVID-19 based on the mechanisms of the oxidative stress, inflammation, and immune response, and to provide a new, safe and efficacious strategy for the better rehabilitation from COVID-19.
KW - COVID-19
KW - HIF-1α
KW - immune response
KW - inflammatory cytokine storm
KW - intermittent hypoxic preconditioning
KW - rehabilitation
UR - http://www.scopus.com/inward/record.url?scp=85105967073&partnerID=8YFLogxK
U2 - 10.3389/fphar.2021.643619
DO - 10.3389/fphar.2021.643619
M3 - Review article
AN - SCOPUS:85105967073
SN - 1663-9812
VL - 12
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 643619
ER -